RNA interference-mediated secretory clusterin gene silencing inhibits proliferation and promotes apoptosis of human non-small cell lung cancer cells

Hepato-Gastroenterology

Volumn 60, Issue 122, 2013, Pages 70-75

  Yan, Yufeng ^a,b   Luo, Kai ^b   Zhang, Huiqin ^a   Chai, Weiran ^b  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Apoptosis; NSCLC; PI3K AKT pathway; Proliferation; Secretory clusterin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CLUSTERIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA INTERFERENCE; WESTERN BLOTTING;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CLUSTERIN; HUMANS; LUNG NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84877708449     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/11801     Document Type: Article

References (27)

1. O'Sullivan J, Whyte L, Drake J, Tenniswood M: Alterations in the post-translational modification and intracellular trafficking of clusterin in MCF-7 cells during apoptosis. Cell Death Differ 2003; 10:914-927. (Pubitemid 36939702)
2. Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA: Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem 2003; 278:11590-11600. (Pubitemid 36792721)
3. Moretti RM, Marelli MM, Mai S, et al.: Clusterin isoforms differentially affect growth and motility of prostate cells: possible implications in prostate tumorigenesis. Cancer Res 2007; 67:10325-10333. (Pubitemid 350070807)
4. Tenniswood M, Flanagan L, Whyte L, Chatterjee N: Effects of clusterin over-expression on metastatic progression and therapy in breast cancer. BMC Cancer 2010; 10:107.
5. Scaltriti M, Santamaria A, Paciucci R and Bettuzzi S: Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells1. Cancer Res 2004; 64:6174-6182. (Pubitemid 39129419)
6. Shannan B, Seifert M, Leskov K, et al.: Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ 2006; 13:12-19.
7. Tenniswood MP, Guenette RS, Lakins J, et al.: Active cell death in hormone-dependent tissues. Cancer Metastasis Rev 1992; 11:197-220.
8. Faivre S, Kroemer G and Raymond E: Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006; 5:671-688. (Pubitemid 44151605)
9. Engelman JA: Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9:550-562.
10. Downward J: Targeting RAS and PI3K in lung cancer. Nat Med 2008; 14:1315-1316.
11. Gustafson AM, Soldi R, Anderlind C, et al.: Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci Transl Med 2010; 2:26ra25.
12. Luo J, Manning BD and Cantley LC: Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003; 4:257-262. (Pubitemid 37329790)
13. Wang J, Zhang N, Li B, et al.: Decline of serum CYFRA21-1 during chemoradiotherapy of NSCLC: a probable predictive factor for tumor response. Tumour Biol 2011; 32:689-695.
14. Ko JC, Hong JH, Wang LH, et al.: Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells. Mol Cancer Ther 2008; 7:3632-3641.
15. Gridelii C, Rossi A and Maione P: Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Oncogene 2003; 22:6629-6638. (Pubitemid 37372343)
16. Pallis AG, Serfass L, Dziadziusko R, et al.: Targeted therapies in the treatment of advanced/metastatic NSCLC. Eur J Cancer 2009; 45:2473-2487.
17. Carney DN: Lung cancer-time to move on from chemotherapy. N Engl J Med 2002; 346:126-128.
18. Mineva I, Stamenova M, Gartner W, Wagner L: Expression of the small heat shock protein alphaB-crystallin in term human placenta. Am J Reprod Immunol 2008; 60:440-448.
19. Stahel RA and Zangemeister-Wittke U: Antisense oligonucleotides for cancer therapy-an overview. Lung Cancer 2003; 41(1):S81-88. (Pubitemid 36818999)
20. Leech SH, Olie RA, Zangemeister-Wittke U: Use of antisense oligonucleotides for therapy. Manipulation of apoptosis inhibitors for destruction of lung cancer cells. Methods Mol Med 2003; 75:655-670.
21. Orr RM and Dorr FA: Clinical studies of antisense oligonucleotides for cancer therapy. Methods Mol Med 2005; 106:85-111.
22. Jansen B and Zangemeister-Wittke U: Antisense therapy for cancer-the time of truth. Lancet Oncol 2002; 3:672-683. (Pubitemid 35314910)
23. Petropoulou C, Trougakos IP, Kolettas E, Toussaint O, Gonos ES: Clusterin/apolipoprotein J is a novel biomarker of cellular senescence that does not affect the proliferative capacity of human diploid fibroblasts. FEBS Lett 2001; 509:287-297. (Pubitemid 34015959)
24. Suzuki M, C. Goetz E, Veneziano G, et al.: Secretory clusterin (sCLU) is a hallmark sensor of DNA damage, cell stress, and cellular senescence: Evidence for similar regulation of sCLU expression after cellular stress and replicative senescence. International Congress Series 2007; 1299:150-157.
25. Zellweger T, Miyake H, July LV, Akbari M, Kiyama S and Gleave ME: Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 2001; 3:360-367. (Pubitemid 32801886)
26. Jo H, Jia Y, Subramanian KK, Hattori H and Luo HR: Cancer cell-derived clusterin modulates the phosphatidylinositol 3′-kinase-Akt pathway through attenuation of insulin-like growth factor 1 during serum deprivation. Mol Cell Biol 2008; 28:4285-4299. (Pubitemid 351904951)
27. Zou Y, Goetz EM, Suzuki M and Boothman DA: Secretory clusterin is a marker of tumor progression regulated by IGF-1 and wnt signaling pathways. In: Radiation health risk sciences. Nakashima M, Takamura N, Tsukasaki K, Nagayama Y and Yamashita S (eds.) Springer Japan 2009; 204-211.